All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

HLA class I and II diversity contributes to the etiologic heterogeneity of non-Hodgkin lymphoma subtypes

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F18%3A00078017" target="_blank" >RIV/00209805:_____/18:00078017 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216224:14110/18:00106857

  • Result on the web

    <a href="http://cancerres.aacrjournals.org/content/78/14/4086.full-text.pdf" target="_blank" >http://cancerres.aacrjournals.org/content/78/14/4086.full-text.pdf</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1158/0008-5472.CAN-17-2900" target="_blank" >10.1158/0008-5472.CAN-17-2900</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    HLA class I and II diversity contributes to the etiologic heterogeneity of non-Hodgkin lymphoma subtypes

  • Original language description

    A growing number of loci within the human leukocyte antigen (HLA) region have been implicated in non-Hodgkin lymphoma (NHL) etiology. Here, we test a complementary hypothesis of &quot;heterozygote advantage&quot; regarding the role of HLA and NHL, whereby HLA diversity is beneficial and homozygous HLA loci are associated with increased disease risk. HLA alleles at class I and II loci were imputed from genome-wide association studies (GWAS) using SNP2HLA for 3,617 diffuse large B-cell lymphomas (DLBCL), 2,686 follicular lymphomas (FL), 2,878 chronic lymphocytic leukemia/small lymphocytic lymphomas (CLL/SLL), 741 marginal zone lymphomas (MZL), and 8,753 controls of European descent. Both DLBCL and MZL risk were elevated with homozygosity at class I HLA-B and -C loci (OR DLBCL 1/4 1.31, 95% CI 1/4 1.06-1.60; OR MZL 1/4 1.45, 95% CI 1/4 1.12-1.89) and class II HLA-DRB1 locus (OR DLBCL 1/4 2.10, 95% CI 1/4 1.24-3.55; OR MZL 1/4 2.10, 95% CI 1/4 0.99-4.45). Increased FL risk was observed with the overall increase in number of homozygous HLA class II loci (P trend &lt; 0.0001, FDR 1/4 0.0005). These results support a role for HLA zygosity in NHL etiology and suggests that distinct immune pathways may underly the etiology of the different NHL subtypes. Significance: HLA gene diversity reduces risk for non-Hodgkin lymphoma.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30204 - Oncology

Result continuities

  • Project

    <a href="/en/project/LO1413" target="_blank" >LO1413: RECAMO2020</a><br>

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Others

  • Publication year

    2018

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Cancer research

  • ISSN

    0008-5472

  • e-ISSN

  • Volume of the periodical

    78

  • Issue of the periodical within the volume

    14

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    12

  • Pages from-to

    4086-4096

  • UT code for WoS article

    000439199100028

  • EID of the result in the Scopus database

    2-s2.0-85050829279